ReviewJournal for immunotherapy of cancer2024
Ten challenges and opportunities in computational immuno-oncology.
Abstract readReview
In one paragraph
Review in Journal for immunotherapy of cancer, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 2 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 2 pooled it
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Global hotspots and trends in pre-metastatic niche research: a bibliometric analysis(2005-2024).Frontiers in immunology · 2025Pooled it
- Correlation does not equal causation: the imperative of causal inference in machine learning models for immunotherapy.Frontiers in immunology · 2025Pooled it
- CosMxScope: Scalable Reconstruction and Digital Pathology Integration of Imaging-Based Spatial Transcriptomics Data.bioRxiv : the preprint server for biology · 2026Article
- Transcriptomic-guided whole-slide image classification for molecular subtype identification.PLoS computational biology · 2026Article
- Navigating the landscape of personalized oncology: overcoming challenges and expanding horizons with computational modeling.Journal of the American Medical Informatics Association : JAMIA · 2026Article
- Harnessing multi-omics and machine learning for predicting immune checkpoint blockade responses: Advances, challenges, and future directions.Fundamental research · 2026Review
- Advances and challenges in immunotherapy and molecular imaging for hepatocellular carcinoma.Discover oncology · 2025Review
- Overcoming resistance to anti-PD-L1 immunotherapy: mechanisms, combination strategies, and future directions.Molecular cancer · 2025Review
- Improvement of the Anticancer Efficacy of PD-1/PD-L1 Blockade: Advances in Molecular Mechanisms and Therapeutic Strategies.MedComm · 2025Review
- Article
- Immunotherapy biomarkers in brain metastases: insights into tumor microenvironment dynamics.Frontiers in immunology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
26 authors.
Riyue Bao *UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, Pennsylvania, USA Alan.Hutson@roswellpark.org baor@upmc.edu anantm@emory.edu meerzamd@mail.nih.gov song.liu@roswellpark.org eliezerm_vanallen@dfci.harvard.edu xingyi@chop.edu.ORCID 0000-0002-6105-1704
Alan Hutson *Department of Biostatistics and Bioinformatics, Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA Alan.Hutson@roswellpark.org baor@upmc.edu anantm@emory.edu meerzamd@mail.nih.gov song.liu@roswellpark.org eliezerm_vanallen@dfci.harvard.edu xingyi@chop.edu.
Anant Madabhushi *Emory University, Atlanta, Georgia, USA Alan.Hutson@roswellpark.org baor@upmc.edu anantm@emory.edu meerzamd@mail.nih.gov song.liu@roswellpark.org eliezerm_vanallen@dfci.harvard.edu xingyi@chop.edu.ORCID 0000-0002-4141-8548
Vanessa D Jonsson *Department of Biomolecular Engineering, University of California Santa Cruz, Santa Cruz, California, USA.
Spencer R Rosario *Department of Biostatistics and Bioinformatics, Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA.
Jill S Barnholtz-Sloan *Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland, USA.
Elana J Fertig *Department of Oncology, Johns Hopkins University, Baltimore, Maryland, USA.
Himangi MaratheDepartment of Biostatistics and Bioinformatics, Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA.
Lyndsay HarrisCancer Diagnosis Program, National Cancer Institute Division of Cancer Treatment and Diagnosis, Bethesda, Maryland, USA.
Jennifer AltreuterDana-Farber Cancer Institute, Boston, Massachusetts, USA.
Qingrong ChenCenter for Biomedical Informatics and Information Technology, National Cancer Institute, Rockville, Maryland, USA.
James DignamDepartment of Public Health Sciences, University of Chicago Division of the Biological Sciences, Chicago, Illinois, USA.
Andrew J GentlesDepartment of Pathology, Stanford University, Stanford, California, USA.
Edgar Gonzalez-KozlovaPrecision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Sacha GnjaticPrecision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Erika KimInformatics and Data Science Program, Center for Biomedical Informatics and Information Technology, National Cancer Institute, Bethesda, Maryland, USA.
Mark LongDepartment of Biostatistics and Bioinformatics, Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA.ORCID 0000-0003-1120-8176
Martin MorganDepartment of Biostatistics and Bioinformatics, Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA.
Eytan RuppinCancer Data Science Laboratory, National Cancer Institute, Bethesda, Maryland, USA.ORCID 0000-0003-4299-7657
David Van ValenDivision of Computing and Mathematical Science, Caltech, Pasadena, California, USA.
Hong ZhangDepartment of Biostatistics and Bioinformatics, Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA.
Natalie VokesDepartment of Thoracic and Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.ORCID 0000-0002-3766-5335
Daoud MeerzamanCenter for Biomedical Informatics and Information Technology, National Cancer Institute, Rockville, Maryland, USA Alan.Hutson@roswellpark.org baor@upmc.edu anantm@emory.edu meerzamd@mail.nih.gov song.liu@roswellpark.org eliezerm_vanallen@dfci.harvard.edu xingyi@chop.edu.
Song LiuDepartment of Biostatistics and Bioinformatics, Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA Alan.Hutson@roswellpark.org baor@upmc.edu anantm@emory.edu meerzamd@mail.nih.gov song.liu@roswellpark.org eliezerm_vanallen@dfci.harvard.edu xingyi@chop.edu.
Eliezer M Van AllenHarvard Medical School, Boston, Massachusetts, USA Alan.Hutson@roswellpark.org baor@upmc.edu anantm@emory.edu meerzamd@mail.nih.gov song.liu@roswellpark.org eliezerm_vanallen@dfci.harvard.edu xingyi@chop.edu.ORCID 0000-0002-0201-4444
Yi XingCenter for Computational and Genomic Medicine, The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA Alan.Hutson@roswellpark.org baor@upmc.edu anantm@emory.edu meerzamd@mail.nih.gov song.liu@roswellpark.org eliezerm_vanallen@dfci.harvard.edu xingyi@chop.edu.
Funding
UNIVERSITY OF PENNSYLVANIA CAN CTR SUPPORT GRANTP30CA016520 · NCI · UNIVERSITY OF PENNSYLVANIA · PI Robert H. Vonderheide · 1985 to 2026
$222.3MVECTOR CORE FACILITYP30CA047904 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI CHRISTOPHER J. BAKKENIST · 1988 to 2026
$158.0MUNIVERSITY OF TEXAS--SPORE IN LUNG CANCERP50CA070907 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI HEYMACH, JOHN V. · 1996 to 2024
$57.4MWILD TYPE P53-BASED ADJUVANT IMMUNOTHERAPY FOR SCCHNP50CA097190 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI Heath Devin Skinner · 2004 to 2026
$49.6MYale SPORE in Skin CancerP50CA121974 · NCI · YALE UNIVERSITY · PI MARCUS W BOSENBERG, Harriet M. Kluger · 2006 to 2026
$43.9MHigh-Dimensional Immune Monitoring of NCI-Supported Immunotherapy TrialsU24CA224319 · NCI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI Sacha Gnjatic, Seunghee Kim-Schulze · 2017 to 2026
$21.5MStanford Cancer Immune Monitoring and Analysis Center (CIMAC)U24CA224309 · NCI · STANFORD UNIVERSITY · PI Sean Curtis Bendall, Holden T. Maecker · 2017 to 2026
$19.9MRPCI-UPCI Ovarian Cancer SPOREP50CA159981 · NCI · ROSWELL PARK CANCER INSTITUTE CORP · PI MOYSICH, KIRSTEN B., ODUNSI, KUNLE · 2013 to 2025
$19.6MCancer Immune Monitoring and Analysis CenterU24CA224331 · NCI · DANA-FARBER CANCER INST · PI FRANK S HODI, Catherine Ju-Ying Wu · 2017 to 2026
$18.4MPhysician Scientist Training in Cancer ResearchT32CA009172 · NCI · DANA-FARBER CANCER INSTITUTE · PI Jennifer R Brown, James A. DeCaprio · 1985 to 2026
$17.1MTranslational Cancer Immune Monitoring and Analysis Center (TCIMAC)U24CA224285 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Gheath Al-Atrash, Cara L Haymaker · 2017 to 2026
$16.7MProject 3: Hedgehog Inhibition to Enhance Response to ICI TherapyP50CA272218 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI FRANCESMARY MODUGNO · 2023 to 2026
$11.0MNCI NIH HHS P30 CA016520NCI NIH HHS P30 CA047904NCI NIH HHS P50 CA070907NCI NIH HHS P50 CA097190NCI NIH HHS P50 CA121974NCI NIH HHS P50 CA159981NCI NIH HHS P50 CA254865NCI NIH HHS P50 CA272218NCI NIH HHS R01 CA124515NCI NIH HHS R01 CA276178NCI NIH HHS R01 CA287673NCI NIH HHS R35 CA253175NCI NIH HHS T32 CA009172NCI NIH HHS U01 CA232758NCI NIH HHS U01 CA233056NCI NIH HHS U01 CA233074NCI NIH HHS U01 CA233078NCI NIH HHS U01 CA233084NCI NIH HHS U01 CA233085NCI NIH HHS U01 CA233096NCI NIH HHS U01 CA233097NCI NIH HHS U01 CA233100NCI NIH HHS U01 CA233102NCI NIH HHS U01 CA239258NCI NIH HHS U01 CA244291NCI NIH HHS U01 CA244314NCI NIH HHS U01 CA244452NCI NIH HHS U01 CA247573NCI NIH HHS U24 CA224285NCI NIH HHS U24 CA224309NCI NIH HHS U24 CA224316NCI NIH HHS U24 CA224319NCI NIH HHS U24 CA224331NCI NIH HHS U24 CA232979NCI NIH HHS U24 CA233032NCI NIH HHS U24 CA274159NCI NIH HHS U54 CA244438NCI NIH HHS U54 CA244711NCI NIH HHS U54 CA244719NCI NIH HHS U54 CA244726NCI NIH HHS UG3 CA244687NCI NIH HHS UG3 CA244697NIAAA NIH HHS U01 AA027681NIAID NIH HHS U01 AI156189NIAMS NIH HHS U01 AR077511NIDCR NIH HHS R01 DE031729NIDCR NIH HHS U01 DE028227NIDCR NIH HHS U01 DE028233NIDCR NIH HHS U01 DE029188NIDCR NIH HHS U01 DE029255NIDDK NIH HHS U01 DK124165
Abstract
Immuno-oncology has transformed the treatment of cancer, with several immunotherapies becoming the standard treatment across histologies. Despite these advancements, the majority of patients do not experience durable clinical benefits, highlighting the imperative for ongoing advancement in immuno-oncology. Computational immuno-oncology emerges as a forefront discipline that draws on biomedical data science and intersects with oncology, immunology, and clinical research, with the overarching goal to accelerate the development of effective and safe immuno-oncology treatments from the laboratory to the clinic. In this review, we outline 10 critical challenges and opportunities in computational immuno-oncology, emphasizing the importance of robust computational strategies and interdisciplinary collaborations amid the constantly evolving interplay between clinical needs and technological innovation.
Indexed as
ImmunotherapyMedical OncologyNeoplasmsComputational BiologyHumansBiomarkerEducationImmune related adverse event - irAEImmunotherapyStatistics
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.